Literature DB >> 12572870

Intestinal microflora as a therapeutic target in inflammatory bowel disease.

Keiichi Mitsuyama1, Atsushi Toyonaga, Michio Sata.   

Abstract

Although the causes of inflammatory bowel disease (IBD) remain incompletely understood, increasing evidence implicates intestinal microflora in the pathogenesis of these disorders. Alteration of intestinal flora therefore may offer a plausible therapeutic approach. Although recent data support a potential therapeutic role for probiotics and prebiotics in patients with IBD, such treatments need to be further assessed by large, double-blind controlled trials. A better understanding of the intestinal microflora and the mechanisms of their action may help us to develop more effective treatment for IBD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12572870     DOI: 10.1007/BF03326418

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  28 in total

Review 1.  Probiotics in inflamatory bowel disease.

Authors:  F Shanahan
Journal:  Gut       Date:  2001-05       Impact factor: 23.059

2.  Germinated barley foodstuff feeding. A novel neutraceutical therapeutic strategy for ulcerative colitis.

Authors:  O Kanauchi; T Iwanaga; K Mitsuyama
Journal:  Digestion       Date:  2001       Impact factor: 3.216

Review 3.  Pre-, pro- and synbiotics.

Authors:  S Bengmark
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2001-11       Impact factor: 4.294

4.  Ispaghula husk may relieve gastrointestinal symptoms in ulcerative colitis in remission.

Authors:  C Hallert; M Kaldma; B G Petersson
Journal:  Scand J Gastroenterol       Date:  1991-07       Impact factor: 2.423

Review 5.  Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics.

Authors:  G R Gibson; M B Roberfroid
Journal:  J Nutr       Date:  1995-06       Impact factor: 4.798

6.  Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease?

Authors:  H A Malchow
Journal:  J Clin Gastroenterol       Date:  1997-12       Impact factor: 3.062

7.  Butyrate oxidation is impaired in the colonic mucosa of sufferers of quiescent ulcerative colitis.

Authors:  M A Chapman; M F Grahn; M A Boyle; M Hutton; J Rogers; N S Williams
Journal:  Gut       Date:  1994-01       Impact factor: 23.059

8.  Treatment of ulcerative colitis with germinated barley foodstuff feeding: a pilot study.

Authors:  K Mitsuyama; T Saiki; O Kanauchi; T Iwanaga; N Tomiyasu; T Nishiyama; H Tateishi; A Shirachi; M Ide; A Suzuki; K Noguchi; H Ikeda; A Toyonaga; M Sata
Journal:  Aliment Pharmacol Ther       Date:  1998-12       Impact factor: 8.171

9.  Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD)

Authors:  R Duchmann; I Kaiser; E Hermann; W Mayet; K Ewe; K H Meyer zum Büschenfelde
Journal:  Clin Exp Immunol       Date:  1995-12       Impact factor: 4.330

10.  Comparison of the effects of psyllium and wheat bran on gastrointestinal transit time and stool characteristics.

Authors:  J Stevens; P J VanSoest; J B Robertson; D A Levitsky
Journal:  J Am Diet Assoc       Date:  1988-03
View more
  4 in total

Review 1.  Potential uses of probiotics in clinical practice.

Authors:  Gregor Reid; Jana Jass; M Tom Sebulsky; John K McCormick
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

2.  Effects of probiotic on intestinal mucosa of patients with ulcerative colitis.

Authors:  Hai-Hong Cui; Cun-Long Chen; Ji-De Wang; Yu-Jie Yang; Yong Cun; Jin-Bao Wu; Yu-Hu Liu; Han-Lei Dan; Yan-Ting Jian; Xue-Qing Chen
Journal:  World J Gastroenterol       Date:  2004-05-15       Impact factor: 5.742

3.  Apoptosis inhibitor expressed by macrophages tempers autoimmune colitis and the risk of colitis-based carcinogenesis in TCRalpha-/- mice.

Authors:  Ikuko Haruta; Noriyuki Shibata; Yoichiro Kato; Masanori Tanaka; Makio Kobayashi; Hidetoshi Oguma; Keiko Shiratori
Journal:  J Clin Immunol       Date:  2007-07-06       Impact factor: 8.317

4.  Lovastatin derivative dehydrolovastatin ameliorates ulcerative colitis in mice by suppressing NF-κB and inflammatory cytokine expression.

Authors:  Xu Zhang; Qing-Hua Deng; Jian-Hua Deng; Sheng-Ju Wang; Qiu Chen
Journal:  Korean J Physiol Pharmacol       Date:  2020-02-20       Impact factor: 2.016

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.